AZD1656   Click here for help

GtoPdb Ligand ID: 7701

Synonyms: AZD 1656 | AZD-1656
Compound class: Synthetic organic
Comment: AZD1656 activates glucokinase (GCK; P35557). AZD1656 was developed as a potential treatment for diabetes. This compound is included in AstaZeneca's Open Innovation Pharmacology Toolbox.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 11
Topological polar surface area 128.66
Molecular weight 478.2
XLogP 1.21
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COCC(Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1ncc(nc1)C)C
Isomeric SMILES COC[C@@H](Oc1cc(Oc2ncc(nc2)C(=O)N2CCC2)cc(c1)C(=O)Nc1ncc(nc1)C)C
InChI InChI=1S/C24H26N6O5/c1-15-10-27-21(12-25-15)29-23(31)17-7-18(34-16(2)14-33-3)9-19(8-17)35-22-13-26-20(11-28-22)24(32)30-5-4-6-30/h7-13,16H,4-6,14H2,1-3H3,(H,27,29,31)/t16-/m0/s1
InChI Key FJEJHJINOKKDCW-INIZCTEOSA-N
References
1. AstraZeneca. 
AZD1656.
Accessed on 17/09/2014. Modified on 17/09/2014. astrazeneca.com, http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1656/
2. Ericsson H, Röshammar D, Wollbratt M, Heijer M, Persson M, Ueda S, Leonsson-Zachrisson M, Norjavaara E. (2012)
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
Int J Clin Pharmacol Ther, 50 (11): 765-77. [PMID:22943931]